AXSM Live signals | Maximize Profits with Getagraph.com

BUY 784 min ago

@ $70.49

Issued: 25 Apr 2024 @ 11:35

Return: 1.46%

Previous signal: Apr 24 - 15:43

Previous signal: Sell

Return: -0.25 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States...

Stats
Today's Volume	412 253
Average Volume	726 472
Market Cap	3.39B
EPS	$0 ( 2024-02-20 )
Next earnings date	( $-1.210 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.57
ATR14	$2.94 (4.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Jacobson Mark L.	Buy	24 662	Common Stock
2024-04-01	Jacobson Mark L.	Sell	24 662	Stock Option (Right to Buy)
2024-04-01	Jacobson Mark L.	Sell	24 662	Common Stock
2024-03-14	Jeffs Roger	Buy	16 976	Common Stock
2024-03-14	Jeffs Roger	Buy	13 000	Common Stock

INSIDER POWER
55.09
Last 99 transactions
Buy: 2 269 939 \| Sell: 680 650

Volume Correlation

Long: -0.16 (neutral)

Short: -0.89 (strong negative)

Signal:(35) Neutral

Axsome Therapeutics Inc Correlation

10 Most Positive Correlations
MMAC	0.888
BOCH	0.879
MIRM	0.876
RNEM	0.87
BATRA	0.869
SINO	0.866
BATRK	0.86
VIRI	0.858
LMRKO	0.854
RAM	0.851

10 Most Negative Correlations
APOP	-0.937
RMRM	-0.915
TDAC	-0.893
MAGS	-0.891
CMLF	-0.868
BHTG	-0.861
VTRU	-0.848
GAINL	-0.847
TRIT	-0.845
SSTI	-0.836

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Axsome Therapeutics Inc Correlation - Currency/Commodity

-0.17
( neutral )

-0.24
( neutral )

0.00
( neutral )

-0.01
( neutral )

0.12
( neutral )

0.01
( neutral )

Axsome Therapeutics Inc Financials

Annual	2023
Revenue:	$270.60M
Gross Profit:	$237.70M (87.84 %)
EPS:	$-5.27

Q4	2023
Revenue:	$71.53M
Gross Profit:	$64.15M (89.69 %)
EPS:	$-2.08

Q3	2023
Revenue:	$57.79M
Gross Profit:	$51.26M (88.70 %)
EPS:	$-1.320

Q2	2023
Revenue:	$46.70M
Gross Profit:	$42.10M (90.15 %)
EPS:	$-1.540

Financial Reports:

No articles found.

Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.